Pictures
OBESITY
sumo
Why this topic? • Medical aspects - connected disorders - medical care - epidemic extent • Non – medical aspects
Why is obesity a problem? • Heart disease. • High blood pressure. • Arthritis. • Diabetes. • Indigestion. • Gallstones. • Some cancers (e.g. breast, prostate). • Snoring and sleep apnoea. • Stress, anxiety, and depression
BACK
COUNTSFacts about overweight and obesity
WHO’s latest projections indicate that globally in 2005: • approximately 1.6 billion adults (age 15+) were overweight; • at least 400 million adults were obese; • at least 20 million children under the age of 5 years are overweight. WHO further projects that by 2015, approximately 2.3 billion adults will be overweight and more than 700 million will be obese.
Introduction • Definition • Physiology • Treatment
What is the obesity? Abnormal or excessive fat accumulation that may impair health
Obesity according to WHO The World Health Organization (WHO) defines "overweight" as a BMI > 25 "obesity" as a BMI > 30
What is BMI? Body Mass Index
KG
BMI = M2
70kg, 1.75m, man BMI = 70/1.75 2 BMI=22.9
BMI CHART
BMI Overweight Adults (%) World
BMI Distribution – Poland, Most recent
BMI Gender Comparison PreObese - Poland
BMI Gender Comparison Overweight - Poland
Why do people develop obesity? 1. Lifestyle 2. Genes
Environmental factors • Reduced need for physical exertion to survive • Increased quality and quantity of avaible food • Nutrition during fetal development on body weight in later life • Stress • Sleep deprivation • Viral infections • Compositions of benign microbial communities within the body
Inborn factors Genes may help explain epidemic extent of obesity to scientists • FTO gene product • Ob.gene product • Adipokines (leptin, adiponectin, resistin,TNF, IL6) • Gut and pancreas hormones(insulin, ghrelin, CCK)
FTO gene • one its variationis linked to obesity • Its carriers are on average 3kg heavier than the rest of population • Double greater risk of obesity • Its role is unknown yet
Ob. gene Product: leptin (satiety hormone) Stimulates: angiogenesis, puberty Action on cell level: muscles, hepatocites, B cells – syntesis adipocites – fat breakdown
Ob.gene Action on system: aim: nucleus arcuatus hipothalami <–> adipocites
(leptin in fetus development)
Is there a Fat-o-Stat? physiology Control mechanisms of cell energy uptake and expenditure
How does it work?
INFORMATION STORED ENERGY STATUS • Circulating leptin indicates how much fat body contain
METABOLIC STATUS • Circulating glucose represents energy immediately available to cells • Various indicators of liver activity signal that ingested energy is being processed
FEEDING STATUS • Neural and chemical signals from the gut indicate whether digestive organs are full of food
BRAIN – COMMAND CENTER APPETITE CONTROL LOCATION: • nucleus arcuatus hypothalami • nucleus solitarius
NUCLEUS HIPOTHALAMI
LEPTIN
Mixed massages
Evolutionary trap Changes in diet and organism tricks to maintain stable weight when significantly alter energy intake • Sudden food restriction • Intentional overfeeding Observation of physiological and behavioral changes
Overriding obesity SIBUTRAMINE Raises available serotonin and norepinephrine, brain chemicals that affect appetite as well as mood and other functions
RIMONABANT Suppresses activity of CB1 receptors in brain and body tissues, which stimulate appetite and are involved in cellular fat processing(not approved in U.S.)
ORLISTAT Blocks fat absorption in intestines to reduce calorie intake
Overriding obesity BARIATRIC SURGERY Reduces and/or bypasses stomach pouch and part of intestine to decrease the amount of food taken in and digested. Also lowers appetite by changing intestine’s hormonal responses to food
Overriding obesity – new approaches APPETITE • Block activity of the appetite-stimulating neuropeptides MCH or NPY or gut peptide ghrelin • Boost appetite-suppressing activity of cellular MC4 receptors or certain serotonin receptor subtypes • Inhibit neural proteins SOC3 and PTP1B to couteract leptin resistance
Overriding obesity – new approaches ENERGY STORAGE • Reduce fat cells’ intake of energy and manufacture of trigliceride by inhibiting 11BHSD1 enzyme
STORED ENERGY USE Increase rate at which fat cells release trigliceride to bloodstream for use as fuel by stimulating PPAR and beta3-adrenrgic cellular receptors in body tissues Increase FGF21 protein, which causes liver cells to burn fat
MANY SUPPORT GROUPS
Opposite problem?
But this is another topic...
references • What fuels fat? Sci Am. 2007 Sep;297(3):72-81. • http://news.bbc.co.uk/2/hi/health/7230065.stm • http://www.who.int/mediacentre/factsheets/fs311/en/inde x.html • http://www.pulsmed.com.pl/document.php? id=106&pageNo=3&ctgSelect=7&module=menuTree